SavedAdd your journal

Journals / Tüberküloz ve Toraks / 2019 / Cilt: 67 - Sayı: 2

Does exercise capacity, dyspnea level, or quality of life actually predict mortality in patients with COPD? 8-year follow-up

Egzersiz kapasitesi, dispne derecesi veya yaşam kalitesi KOAH hastalarında mortaliteyi yansıtır mı? 8-yıllık izlem

Elif ŞEN
Fatma ÇİFTÇİ
Öznur AKKOCA YILDIZ
Sevgi SARYAL
Pages
83–91
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

At the endof 8-year follow-up period, the relation between these tests and mortality wasexamined.Results: A total of 42 patients with stable COPD were included in the study.Sixteen patients died during the approximately 8-year follow-up period.Univariate analysis revealed that VO2 peak [HR: 1.845; CI: (1.336-2.55); p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: The goals of chronic obstructive pulmonary disease (COPD)treatment are to relieve dyspnea, increase exercise capacity, and improvequality of life.
📊
Key Findings & Data:George’s Respiratory Questionnaire, and exercise capacity with the6-minute walking test (6MWT) and cardiopulmonary exercise test.
💡
Conclusion & Impact:At the endof 8-year follow-up period, the relation between these tests and mortality wasexamined.Results: A total of 42 patients with stable COPD were included in the study.Sixteen patients died during the approximately 8-year follow-up period.Univariate analysis revealed that VO2 peak [HR: 1.845; CI: (1.336-2.55); p
🔬Design:Survey & Empirical Study
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Introduction: The goals of chronic obstructive pulmonary disease (COPD)treatment are to relieve dyspnea, increase exercise capacity, and improvequality of life. The relation of exercise capacity, dyspnea level, and quality oflife with long-term mortality is unclear. Aim of the study was to assess theeffect of exercise capacity, dyspnea level and quality of life on long-termmortality risk in patients with COPD.Materials and Methods: Dyspnea level was assessed using the modifiedMedical Research Council (mMRC), Borg and Baseline Dyspnea Index (BDI)and Body Obstruction Dyspnea Exercise (BODE), health-related quality of lifewith St. George’s Respiratory Questionnaire, and exercise capacity with the6-minute walking test (6MWT) and cardiopulmonary exercise test. At the endof 8-year follow-up period, the relation between these tests and mortality wasexamined.Results: A total of 42 patients with stable COPD were included in the study.Sixteen patients died during the approximately 8-year follow-up period.Univariate analysis revealed that VO2 peak [HR: 1.845; CI: (1.336-2.55); p

Özet

Giriş: Kronik obstrüktif akciğer hastalığı (KOAH)'nda tedavinin amacı dispneyi azaltmak, egzersiz kapasitesini ve yaşam kalitesini arttırmaktır. Egzersiz kapasitesi, dispne düzeyi ve yaşam kalitesi ile uzun dönem mortalite arasındaki ilişki belirsizdir. Bu araştırmanın amacı KOAH hastalarında egzersiz kapasitesi, dispne düzeyi ve yaşam kalitesinin uzun dönem mortalite riskini değerlendirmektir. Materyal ve Metod: Dispne düzeyi “Değiştirilmiş Tıbbi Araştırma Konseyi” (modified Medical Research Council, mMRC), Borg ve Bazal Dispne İndeksi (BDI) ve Vücut Obstrüksiyonu Dispne Egzersizi (BODE), yaşam kalitesi St. George’s Solunum Anketi ve egzersiz kapasitesi 6-dakika yürüme testi (6DYT) ve kardiyopulmoner egzersiz testi ile değerlendirildi. Sekiz-yıllık izlem süresinin sonunda bu testler ve mortalite arasındaki ilişki değerlendirildi. Bulgular: Kırk iki stabil KOAH olgusu araştırmaya alındı. Sekiz-yıllık izlemde 16 hasta öldü. Tek değişkenli analizde pik VO2 [HR: 1.845; CI: (1.336-2.55); p< 0.001], BODE index [HR: 0.787; CI: (0.703-0.880); p< 0.001] ve SGRQ [HR: 1.073; CI: (1.028-1.119); p= 0.001] mortalite riskiyle ilişkili bulundu. Çok değişkenli Cox regresyon analizine gore pik VO2 mortalitenin en anlamlı göstergesiydi [HR: 1.031; CI: (0.683-1.120); p= 0.01]. ROC analizinde pik VO2 < 22.5 değerinin %82 duyarlılık, %80 özgüllük ve 0.142 [95% CI: (0.027-0.257); p< 0.001] AUC değeriyle mortalite riskini gösterdiği saptandı. Sonuç: Maksimal egzersiz sırasında ortaya çıkan kardiyopulmoner kısıtlılıklar uzun dönem mortalite riskinin en önemli göstergesidir.

🔖

Cite This Article

ŞEN, E., ÇİFTÇİ, F., YILDIZ, Ö. A., SARYAL, S. (2022). Does exercise capacity, dyspnea level, or quality of life actually predict mortality in patients with COPD? 8-year follow-up. Tüberküloz ve Toraks, Cilt: 67 - Sayı: 2, 83–91. https://ajindex.com/articles/618388

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. From the global strategy for the diagnosis, management and prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. Available from:
  2. Criner GJ, Bourbeau J, Diekemper RL, Ouellette DR, Goodridge D, Hernandez P, et al. Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest 2015;147:894-942
  3. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-7
  4. ATS. ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 2003;167:211-77
  5. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disabilityin patients with chronic obstructive pulmonary disease. Thorax 1999;54:581-6
  6. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982;14:377-81
  7. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984;85:751-8
  8. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in COPD. N Engl J Med 2004;350:1005-12
  9. Jones PW, Quirk FH, Baveystock CM. The St George’s Respiratory Questionnaire. Respir Med 1991;85:25-31
  10. Casaburi R. Activity promotion: a paradigm shift for chronic obstructive pulmonary disease therapeutics. Proc Am Thorac Soc 2011;8:334-7
  11. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-55
  12. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories: ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-7
  13. Wasserman K, Hansen JE, Sue DY, Casaburi R, Whipp BJ. Principles of Exercise Testing and Interpretation. Third Edition p:130-2
  14. Waschki B, Kirsten A, Holz O, Müller KC, Meyer T, Watz H, et al. Physical activity is the strongest predictor of allcause mortality in patients with COPD: a prospective cohort study. Chest 2011;140: